Compare · AMIX vs MDLN
AMIX vs MDLN
Side-by-side comparison of Autonomix Medical Inc. (AMIX) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMIX and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.26B, about 9770.0x AMIX ($4.6M).
- Over the past year, AMIX is down 73.2% and MDLN is down 15.4% - MDLN leads by 57.8 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 4 for AMIX).
- MDLN has more recent analyst coverage (25 ratings vs 0 for AMIX).
PerformanceAMIX-38.53%MDLN-15.44%
2025-12-17+0.00%2026-06-04
- Company
- Autonomix Medical Inc.
- Medline Inc.
- Price
- $0.38-3.01%
- $34.46-0.01%
- Market cap
- $4.6M
- $45.26B
- 1M return
- +0.08%
- -24.00%
- 1Y return
- -73.23%
- -15.44%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2025
- News (4w)
- 4
- 21
- Recent ratings
- 0
- 25
Latest AMIX
- Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
- SEC Form 10-K filed by Autonomix Medical Inc.
- Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
- Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
- Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
- Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
- Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026
- SEC Form S-8 filed by Autonomix Medical Inc.
- Autonomix Medical to Present at LSI USA '26
- Autonomix Medical Selected for Best Innovation Competition at CRT 2026
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)